The Society of Nuclear Medicine and Molecular Imaging ...



The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is an international scientific and professional organization founded in 1954 to promote the science, technology, and practical application of nuclear medicine. The European Association of Nuclear Medicine (EANM) is a professional nonprofit medical association that facilitates communication worldwide between individuals pursuing clinical and research excellence in nuclear medicine. The EANM was founded in 1985. SNMMI and EANM members are physicians, technologists, and scientists specializing in the research and practice of nuclear medicine. The SNMMI and EANM will periodically define new guidelines for nuclear medicine practice to help advance the science of nuclear medicine and to improve the quality of service to patients throughout the world. Existing practice guidelines will be reviewed for revision or renewal, as appropriate, on their fifth anniversary or sooner, if indicated. Each practice guideline, representing a policy statement by the SNMMI/EANM, has undergone a thorough consensus process in which it has been subjected to extensive review. The SNMMI and EANM recognize that the safe and effective use of diagnostic nuclear medicine imaging requires specific training, skills, and techniques, as described in each document. Reproduction or modification of the published practice guideline by those entities not providing these services is not authorized. Developed 2013THE SNMMI AND EANM PRACTICE GUIDELINE FOR RENAL SCINTIGRAPHY IN ADULTSAuthors: Chairman M. Donald Blaufox, Co-Chairman Diego De Palma committee: Yi Li, Alain Prigent, Martin Samal, Andrea Santos, Zsolt Szabo, Andrew Taylor, Giorgio Testanera, Mark Tulchinsky Keywords:PREAMBLEThe Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the European Association of Nuclear Medicine (EANM) have written and approved guidelines to promote the use of nuclear medicine procedures with high quality. These guidelines are intended to assist practitioners in providing appropriate nuclear medicine care for patients. They are not inflexible rules or requirements of practice and are not intended, nor should they be used, to establish a legal standard of care. For these reasons and those set forth below, the SNMMI and EANM caution against the use of these guidelines in litigation in which the clinical decisions of a practitioner are called into question.The ultimate judgment regarding the propriety of any specific procedure or course of action must be made by medical professionals taking into account the unique circumstances of each case. Thus, an approach that differs from the guidelines does not necessarily imply that the approach was below the standard of care. To the contrary, a conscientious practitioner may responsibly adopt a course of action different from that set forth in the guidelines when, in the reasonable judgment of the practitioner, such course of action is indicated by the condition of the patient, limitations of available resources, or advances in knowledge or technology subsequent to publication of the guidelines.The practice of medicine involves not only the science, but also the art of dealing with the prevention, diagnosis, alleviation, and treatment of disease. The variety and complexity of human conditions make it impossible at times to identify the most appropriate diagnosis or to predict with certainty a particular response to treatment. Therefore, it should be recognized that adherence to these guidelines will not assure an accurate diagnosis or a successful outcome. All that should be expected is that the practitioner will follow a reasonable course of action based on current knowledge, available resources, and the needs of the patient to deliver effective and safe medical care. The sole purpose of these guidelines is to assist practitioners in achieving this objective.INTRODUCTION Renal scans are safe and widely available tests that provide information about the morphology and function of the kidneys utilizing of radiopharmaceuticals with high renal clearance (Sfakianakis, 1988). This information supplements those that obtained by other imaging tools methods (Ultrasound, CT, MRI) (Boubaker 2006, De Palma 2014), especially regarding theit has special value to measure relative renal function.al balance between the kidneys, about the effect of aAnatomical abnormalities affecting causing renal vascularity or the urinary tract malfunctionon renal functioncan be clarified,. sometimes using theThis potential can be enhanced with pharmacological of drugs to that stress the systemrenal functional capability.. Radiopharmaceuticals used to perform renal scans can be divided into three major categories: filtrated filtered by the glomerulus, secreted by the tubules and retained in the tubules via receptor-mediated endocytosis.Functional agents (filtered by the glomerulus and or secreted by the tubules) are used in the dynamic renal scan (or renography), and morphological agents (retained in the tubules) are used in the static (cortical) renal scan.Dynamic scans shows elucidate the uptake and drainage of the radiopharmaceutical, and allows the generation of time-activity curves by selection of regions of interest, whilst while static scans depictsimage the functional renal tissue and may provide useful morphologic information.An uUnderstanding of the principles of the test, its limitations and the sources of error are essential in to the interpretation of the results and effective use of itrenal scintigraphy.GOALSPurpose of this guideline is to give toprovide practitioners a complete summary of radiopharmaceuticals, techniques and consolidated clinical indications for performing renal scintigraphy in adults. This state-of-the-art overview will not deal with radiopharmaceuticals or indications currently under investigation or used for clinical trials or research.DEFINITIONSNot applicableCOMMON CLINICAL INDICATIONSMajor indications (Blaufox 1991) for renal scintigraphy include (Blaufox 1991) but are not limited, to the following:Calculation of the differential (relative) renal function, Measurement of the absolute renal function, either as an approximation of effective renal plasma flow (ERPF) or glomerular filtration rate (GFR).Congenital and acquired renal abnormalitiesAcute renal failureObstructive uropathyRenovascular hypertensionStatus post renal transplantationPyelonephritis and parenchymal scarringOptimal assessment aboutof the existence of an obstructive uropathy normallyusually requires Diuretic diuretic renography (Rado JP, el al 1968, O’Reilly PH, et al 1978, 1992, 1996), i.e. the use of a diuretic drug, such as furosemide, for to maximizing theinitiate a diuresis. This test has become one of most common procedures in daily renal nuclear medicine practice, and is very useful in differential differentiation of obstructive or non-obstructive causes of a dilated renal pelvis (Taylor 2012)., being Diuretic renography is a non-invasive equivalent to the now discarded Whitaker test, which directly measures the intrarenal pelvic hydrostatic pressure. There is a full guideline in preparation devoted to obstructive uropathy.In the case of a suspected renovascular hypertension, it is recommended to perform an an aAngiotensin-converting enzyme inhibition (ACEI) renographyrenogram,. This was first described in 1983 by Majd et all (Majd M, et al 1983). This test ishelps able to diagnose renal vascular hypertension caused by renal artery stenosis (RAS) and to may predict the response to vascular intervention. ACEI renography has been used as a routine nuclear medicine exam for many years. In the era of CT angiography, MR angiography and Doppler vascular sonography the role of captopril renography has changed diminished (Taylor A. 1996, 2006; Prigent 2014). The renal transplant with ATN has poor renal function with evidence of renal cortical retention of MAG3, poor reduced renal uptake of DTPA and poor reduced urine excretion butwith images showing its blood perfusion is relatively better than itspreserved compared to function (Hilson AJ et al 1978, Kirchner PT et al 1978, Li Y, Russell CD, et al 1994). Quantitative methods may be useful in follow-up studies. There are a variety of methods proposed to quantitate evaluate blood flow curve of the transplant kidney, such asincluding Hilson et al’s perfusion index and Kirchner et al’s kidney-to-aorta (K/A) ratio (Hilson AJ et al 1978, Kirchner PT et al 1978). There are quantitative methods for measurement of renal parenchymal (cortical) retention of tubular radiotracers (MAG3 and OIH), such as Tmax and 20/3 min ratio (Li Y, Russell CD, et al 1994) which increase in ATN of the graft. A comprehensive review was published by Dubovsky et al. (1999)Urinary tract infections (UTI) are often clinically only divided as into febrile or non-febrile. Tc-99m DMSA is the best imaging agent to visualize renal parenchymal pathology, allowing helping Pyelonephritis to be distinguished pyelonephritis from lower tract febrile infections acutely. , when performed during the acute phase of the illness. Renal cortical scintigraphy y is usually may be performed to evaluate kidney scarring after pyelonephritis. Scarring must beshould not be assessed not beforeless than six months after the last febrile UTI. (De Palma, 2013)QUALIFICATIONS AND RESPONSIBILITIES OF PERSONNELIn the United States, see Section V of the SNMMI Guideline for General Imaging. In Europe, the certified nuclear medicine physicians who perform the study and sign the report are responsible for the procedure, according tocomplying with national laws and rules.PROCEDURE/SPECIFICATIONS OF THE EXAMINATIONS RequestThe request for the study should include all relevant clinical, laboratory and imaging information. In particular, the nuclear medicine physician should be aware of relevant urologic procedures and surgeries such as the presence of a nephrostomy tube, ureteral stent and or urinary diversion. .The supervising/interpreting nuclear medicine physician should review all available clinical, laboratory, and radiologic data prior to performing the study. Patient preparation and precautionsRenal radionuclide scans generally require no specific preparation:; patients must can avoid fasting, and drinking at least 500 ml of water is recommended. Pregnancy is a usually a contraindication to every radiopharmaceutical administration. Adverse reactions to renal radiopharmaceuticals are quite uncommonrare;: no major reaction has ever been reportedRadiopharmaceuticalsFor When performing the dynamic renal studies, the radiopharmaceuticals can be sub-divided into two categories: 1: High eExtraction rRenal pPlasma fFlow (Approximate ERPF) agents (tubular extraction) including : 131 I-hippuran, 123 I-hippuran, 99mTc-MAG3 (mercaptoacetyl-triglycerine) and 99mTc-EC (ethylenedicysteine). (5,6)and 2: gGlomerular fFiltration agents,: including 99mTc-DTPA (diethylenetriamine pentaacetic acid) and 51-Cr EDTA (ethylendiamine tetraacetic acid)For renal morphologic scintigraphy, Tthe radiopharmaceuticals used for renal morphologic scintigraphy, are 99mTc-DMSA (dimercaptosuccinic acid) and 99mTc-glucoheptonate, both accumulating of which accumulate primarily into the renal cortex. I-131/123 orthoiodohippuran (OIH), is a classic renal tubular agent that has been used as a substitute for para-aminohippurate (PAH), which was introduced by Tubis (Tubis M, et al, 1960). The 131-I label, once used for probe renography, gives yields very low quality images with a high radiation dose and is no longer available.Tc-99m MAG3 (Fritzberg AR, et al, 1986), is similar to OIH (Russell, 1999), although it has having novery little glomerular filtration due to its high plasma protein binding, that results in a lower extraction fraction. (Muller-Suur, 1989). Tc-99m MAG3 now becomes the daily usedis currently the most frequently used Tc-99m labelled renal tubular agent in nuclear medicine practice. For Since its excretion, is more comparable to the secretion rate of proximal renal tubule, Bubeck et al proposed the concept of tubular extraction rate (TER) (Bubeck B, et al, 1987) to replace the term ERPF. Tc-99m DTPA is excreted by glomerular filtration without renal tubular secretion, the same waysimilar to of inulin and creatinine, and was first clinically used clinically in 1970 (Hauser W. et al 1970). There is only 5-10% protein binding bound DTPA in the plasma at after1 hour. DTPA labelled with Tc-99m remains the most suitable radiopharmaceutical for routine combined measurement of GFR and renal imaging. Cr-51 EDTA also has been also commonly used in Europe since 1966 to measure GFR (Stacy BD 1966, Chantler, 1972), Iit is not available in the US and it cannot be used for imaging.Tc-99m DMSA (dimercaptosuccinic acid) (Lin TH, et al 1974) and Tc-99m GH (glucoheptonate) (Boyd RE. et al 1973) were proposed in early 1970s. They are mainly bound in the proximal tubule in the renal cortex for a prolonged time after injection and are suitable for static renal imaging to demonstrate renal mass or defects in the renal parenchyma. These agents are also called renal cortical agents. 99mTc-DMSA is commonly used because of its bigger higher retention in the renal parenchyma (30% vs 5-10% of glucoheptonate). (Willis, 1977) These numbers are approximations and there is some evidence of secretion of DMSA by the distal tubule (Yee et al 1981). Because of its high retention the potential radiation dose of DMSA is significant and the administered dose should be chosen with that in mind.Protocol/image acquisitionStatic Renal Scan (sometimes referred as Renal Cortical scintigraphyRadiopharmaceutical and injected activity: 99mTc-DMSA provides the best images. 99mTc-Glucoheptonate has been used also., Adult Dose: 100 MBq Radiation burden: approximately 1mSvv. (ICRP 80, 1998).General procedure:Previous InformationAll relevant available clinical, biochemical and imaging information must be collected.Patient preparation:Good hydration before and after radiopharmaceutical administrationRadiopharmaceutical Administration: Intravenous injection should mustbe performed, carefully avoiding extravasation.Timing after injection:Image acquisition should start from 2 to 4 hours after radiopharmaceutical injectionadministration. In case of lowIn the presence of poor renal function late images (up to 20 hours after) can be acquired.Patient PositioningSupine position.: Be careful with patient comfort, to reduce motion.Technical Parameters: Static images acquisitionCollimator: HighLow energy, ultra-high Resolution or pinhole (in small children)Minimum Matrix for dynamic scan: 128x128 or 256x256 pixel (newer instruments permit much greater resolution)Zoom: From 1 to 2Total counts/ Time per view: At least 300 000 total counts must be acquired or use fixed time of 5-10 minutes/ per view. If a pinhole collimator is being used, 100 000 to 150 000 total counts or 10 minutes should be acquired per view. Views: Posterior and 30°-35° Posterior Obliques. Anterior view must be acquired inconsidered if there are abnormalities of number, shape and position of the kidneys. SPECT images can be acquired but there is no consensus in its usefulness (Piepsz, 2001)After Imaging:Patient should be advised to maintain hydration and frequent bladder emptying during the rest of the day.Renal dynamic scintigraphyRenal dynamic scintigraphy (sometimes referred as radionuclide renography) refers toconsists of serial imaging after intravenous administration of the selected radiopharmaceutical. This procedure usually involves 2 serial dynamic acquisitions, the first intended to investigate vascular or perfusion phase (this phase is often omitted), followed by the second one needed to evaluatefor functional uptake, cortical transit, and excretion phases. It is recommended also to obtain a a later static imageing after upright standing and bladder voiding. Although these phases are often discussed separately, they all take place virtually simultaneously.Patient preparation:Good hydration before and after radiopharmaceutical administration is essential. Empty theThe patient should void bladder before the beginning of the scan. General adult activityAdult Dose: 99mTc-labeled radiopharmaceuticals: from 90 to 200 MBq. The higher activity is suggested for studying renal perfusion, 123-I Hippuran: 74 MBqWe strongly recommend optimizing protocols according to the ALARA principles Radiation burden: usually, approximately less than 1mSv with the above suggested activities. (ICRP 80, 1998; Stabin, 1992). Specific information is detailed in Tables 1 and 2.General procedure:Previous InformationAll relevant available clinical, biochemical and imaging information must be collected.Radiopharmaceutical administration Intravenous injection should be performed. BA butterfly needle is recommended to avoid extravasation. If requested indicated by clinical indications, furosemide intravenous administration can be performed. The sSuggested dose is 0.5 mg/kg of body weight, max 40 mg. Administration may happen in different moments. The simplestr practice is to administer it the diuretic at the same time as the radiopharmaceutical (so called F+0 protocol). Is it possible toOther options include administer it 20 minutes after radiopharmaceutical injection or 15 minutes before radiopharmaceutical injection (so called F+20 or F-15 protocols). Interpretation of the results must take into account the chosen timing.For clinical indication of rRenovascular hypertension scintigraphy is performed approximately 1 hour after oral administration of 25 to 50 milligrams of captopril or 10 to 20 minutes after intravenous injection of 40 micrograms/kg (maximum 2.5 mg) of enalaprilat. Blood pressure should be measured before administration of the ACE inhibitor and monitored every 10 to 15 minutes. An intravenous line should be considered to be kept in place to allow prompt fluid replacement if the patient becomes hypotensive. The patient should be well hydrated, especially if furosemide is also used to facilitate detection of cortical retention of the radiopharmaceutical. One protocol is to obtain a baseline scan without an ACE inhibitor followed by a repeat examination after administration of an ACE inhibitor on the same or following day. The combined examinations help to detect significant ACE inhibitor induced scintigraphic abnormalities. (Fommei, 1993, Taylor AT Jr, et al 1998)An alternative protocol is to obtain the examination with an ACE inhibitor first. A normal examination indicates a low probability for renovascular hypertension and obviates the need for a baseline examination without an ACE inhibitor. If the examination with an ACE inhibitor is abnormal, a baseline examination is needed as further investigation waiting at least the next day or later. Chronic use of ACE inhibitors may decrease the sensitivity of the test. ACE inhibitors should be discontinued for 3 to 7 days before the test, depending on their half-life. If stopping the patient’s ACE inhibitor is not possible, the study may still be performed. (Fommei, 1993) but the sensitivity is decreased.Timing after injection and scan framing:A commonly used technique involves dynamic acquisition of 1-2 second images for 1 min. (vascular phase (first phase)), starting immediately after radiopharmaceutical administration. It is followed by 10-20 second images (functional uptake , cortical transit (second phase),), and then 20-30 sec. images (excretion phases (third phase)). Always acquire a post-micturition post-erect image, for the same time duration of as the last frame of the renogram. The compatibility between the acquisition protocol and the processing software must be checked in advance.Patient PositioningSupine position: Be careful with patient comfort, to reduce motion. In patients with particularwho cannot lie flat clinical condition is it is possible to perform the exam seated with the back on gamma-camera detector, but this may lead to important errorsTechnical Parameters Dynamic images acquisitionCollimator: [Low Energy – High resolution or General purpose, according to availability Minimum Matrix: 64x64 or 128 x128 pixelZoom: 1Views: Posterior. Anterior views must be acquired in the presence of horseshoe or ectopic kidney conditions or in other particular requestssituations where the kidney is anterior such as kidney allograft evaluation. Lateral views may be obtained at the end of the renography if renal depth measurements are requested needed.Frame time (flowfirst phase): 1-5 seconds/frame for 1 minuteFrame time (functionsecond phase): 10-20 seconds/frame for 5-10 minutesFrame time (excretionthird phase): 20-30 seconds/frame for at least 20 min Total max time 20-30 minutesAdditional images after bladder emptying or delayed post-erect images, of the same duration of as the last frame of the renogram are useful.After ImagingPatient should be advised to maintain hydration and frequent bladder emptying during the rest of the day.ProcessingSplit (relative, differential) renal functionThe aAccuracy and reproducibility of the measurement of split renal function (SRF) depends on kidney size and kidney function. The sSmaller the kkidneys and those with e lower theirreduced function, are associated with the lower the accuracy and precision of the measurement of split renal function. Other factors affecting accuracy are intrarenal vascular and extra-renal (extravascular and vascular) background, attenuation, and scatter. Main sources of error in the measurement of split renal function are background activity and attenuation [Piepsz, 1990; Lythgoe, 1999; Caglar, 2008; Lezaic, 2008]. The measurement of SRF with static renal scintigraphy requires the tracing ofdrawing a Rregion of Iinterest (ROIs) around each kidney and to calculate the percent contribution of each kidney counts to total counts. The subtraction of area-normalized background ROIs is not strictly necessary in patients with good renal function, whilst but it is mandatory in case of poor renal function (Piepsz,2001) Unfortunately, in the case of poor renal function the errors of the measurement increase. (Fine EJ, Blaufox MD On Behalf of the Albert Einstein College of Medicine/Cornell University Medical Center Collaborative Hypertension Group 1991) The measurement of SRF with dynamic renal scintigraphy requires the tracing ofdrawing a rRegion of iInterest (ROIs) around each kidney and the generation of curves (renograms) from each ROI after the subtraction of area-normalized background ROIs. The most accurate background ROIs are C-shaped surrounding the lower, lateral and upper part of the kidney. The SRF is then calculated with a mathematical algorithm applied to the uptake part of the curve.The recommended time periods are60”-120” after the appearance of the tracer in the aorta for 123-I hippuran90’”-150’” for 99mTc MAG3 or EC120’-180’” for 99mTc DTPAThere are two models equally accurate,of equivalent accuracy; the slope method with the Patlak-Rutland (Rutland, 1983) plot and the integral method. (Gordon, 2011) A recent report suggests a method using liver activity to help with the normalization but it has not yet been confirmed fully (Blaufox 2016)In the measurement of split renal function, aAttenuation correction usually is not necessary providing if the distance of the left and right kidneys from the detector is approximately the same so that both kidney counts are attenuated to the same extent (Prigent, 1999). If itIt is necessary to correct for attenuation in the patients with ectopic or misplaced or displaced kidneys., Tthe method of choice is to measure split renal function in using the geometric mean image calculated pixel wise from conjugate combined posterior and anterior views, using for the scan a two head gamma camera for the scan (Delpassand, 2000)Total (absolute) renal function (In Vitro methods)Total renal function may be performed with renal scintigraphy to obtain quantitative functional data. The measurement of absolute renal function (GFR and ERPF) using radionuclides is a unique technique to assess renal function, especially in patients with unilateral renal abnormalities, and can be made using radiopharmaceuticals with corresponding excretion way. . This is a non-invasive and accurate methodology (Blaufox 1996). Several methods have been introduced for this purpose (Schlegel, 1976, Tauxe, 1982, Gates, 1982, Bubeck, 1987, Taylor, 1995, Itoh, 2003),; according to the radiopharmaceutical injected, using different ways to evaluate injected activity and plasma disappearance or renal uptakethe timing of the blood samples depends on the radiopharmaceutical injected. To ensure a correct evaluation of GFR and renal function, 1-minute static imaging acquisition of the syringe with the dose to be injected is performed. The same 1-minute static imaging acquisition is performed of the empty syringe that must be conserved after patient injection. Linearity of the activity / counting ratio must be ensured, if necessary using shielding with a known attenuation factor. If extravasation is suspected, injection point must be counted with the parameters below. Well counter connected with gamma camera workstation may be used instead of gamma camera acquisition of full and empty syringe.Most methods for the measurement of total renal function rely upon regression formulas. They are derived from a sum of renal counts in posterior projection accumulated over uptake interval, corrected for radioactive decay, background, attenuation and scatter, and related to plasma clearance of a radiopharmaceutical assessed from several blood samples withdrawn over extended period of time. Regression methods should be applied exactly as it is recommended in their original description otherwise the regression equations are invalid. Accuracy of the regression methods can be affected by differences between patient population in a specific department and the group of patients examined to obtain regression equations. Therefore multicenter studies and independent validation of the regression techniques are required but they are still mostly missing. Reports on regression methods usually do not specify proper prediction errors.Due to these limitations, some authors decline to measure total renal function in renal scintigraphy at all, and recommend using only plasma clearance techniques based on blood sampling for the purpose [Gordon 2011]. Individual kidney function is then obtained from total renal function measured by plasma (or urinary) clearance using split renal function measured by scintigraphy. Providing the measurement of plasma clearance and renal scintigraphy are performed with two different tracers (one filtered and one secreted), it should be noted that, under pathological conditions, filtration fraction may not be the same in both kidneys [Prigent 1999].Up to our knowledge, the only regression method that have been validated in several departments and reported to provide good results was developed by Taylor et al [Taylor 1995, 1997, Bocher 2001, Esteves 2006a, 2006b, Samal 2011].InterpretationInterpretation of the scan is highly dependent on s can be affected by the radiopharmaceutical used for imaging. The radiopharmaceutical that is most frequently used at present is Tc-99m MAG3 (mercaptoacetyltriglycine). Tc-99m DTPA (diethyl-triamino-pentaacetic acid) is used less frequently. can be in most situations for the same indications but the images are not as good and there is greater background. This disadvantage is offset to some degree by the lower associated radiation dose. The extraction of Tc-99m DTPA delivered to the glomerulus is nearly complete and its renal clearance of Tc-99m DTPA describes approximates the glomerular filtration rate (GFR), and can be considered the best radiopharmaceutical for differentiation between acute transplant rejection and ATN is Tc-99m DTPA since it provides better separation between the vascular (perfusion) and tubular phases of tracer transport.. The vascular (perfusion)first phase phase provides a qualitative assessment of renal blood flow to the kidneys and helps assesswhen administered in a higher dose helps evaluate vascular compromise and to differentiate ATN from acute transplant rejection. Relatively preserved perfusion at with reduced function is also seen in acute contrast nephropathy.Tc-99m MAG3 has significantis bound by plasma protein binding significantly so that its glomerular filtration is minimal while the effective first pass extraction fraction is about 50-60 %. Tc-99m MAG3 is preferred over Tc-99m DTPA for functional imaging of the kidneys because of its rapid accumulation in the kidney parenchymatubules and effective excretion through the collecting system.. A 3 fold excretion results in better display of functional renal parenchyma and more efficient assessment of urinary tract patency. Although it is less suited to differentiate preserved perfusion from function in ATN because of the radiation associated with a high dose, it is more effective in detecting renal outflow obstruction, renal transplant dysfunction, renal trauma and posttraumatic or iatrogenic urinary leaks.Nephrotoxic drugs can prolong parenchymal radiotracer transit and depending on the severity of toxicity damage and also result in reduced parenchymal uptake. Nephrotoxic drugs include cyclosporine, aminoglycosides and cytotoxic chemotherapy drugs. Most cytotoxic drugs cause tubulo-interstitial injury: carboplatin, cetuximab, cyclophsophamide, ifosmamide, interferons, methotrexate, pantumumab, streptozocin. Others affect the vasculature and renal perfusion: bevacizumab, gemcitabine, interleukin 2, mitomycin C, nitrosoureas, sorafenib, sunitinib. Space occupying lesions can be detected by functional imaging as parenchymal defects. Ultrasound, CT and MR imaging are best suited for evaluation of space occupying lesions and should be recommended when regional defects in parenchymal function are detected. Functional imaging may play a role before surgical interventions to assess residual renal function after partial or complete unilateral nephrectomy.Pseudo- tumors of the kidneys are non-malignant masses that can mimic renal tumors. They can have a developmental etiology with normal parenchymal function such as persistent fetal lobulation, dromedary hump, or prominent columns of Bertin. Infectious / inflammatory diseases will result in reduced parenchymal function. Infectious diseases with renal cortical defects on the scan include focal pyelonephritis, renal abscess, and post pyelonephritic scarring. Examples of inflammatory diseases with focally or regionally decreased parenchymal function are xanthogranulomatous pyelonephritis and sarcoidosis. Other examples of renal pseudo tumors with decreased parenchymal function are arteriovenous malformations, hematomas and extramedullary hematopoiesis.While in the past radionuclide imaging was used extensively for differentiation of ATN from acute rejection, today it is mostly used for diagnosis of surgical complications such as urinary leakage, renal artery stenosis, or obstruction. Another important cause of urinoma is renal trauma. While CT, US or MRI provide exquisite details of the anatomical changes, scintigraphy can help assess regional kidney function and rule out urine leakage. SPECT/CT at the end of a functional study will provides localization of an urinoma. Special Considerations for childrenSee Pediatric guidelinesVII. DOCUMENTATION AND REPORTING The report should contain the essential elements required to evaluate and interpret the study and aims to communicate the results to the referring physician in a clear and concise manner designed to optimize patient care (1-5). I - Study identificationPatient name and surname, and medical record number or patient code, if appropriateAge or date of birth and gender.Date of study (and time of different acquisitions if relevant).Type of renal test such as radionuclide renography (and eventually either diuresis renography or captopril renography if applicable), renal cortical scintigraphy (eventually renal cortical SPECT) or evaluation of renal allograft. Administered dose and identity of radiopharmaceuticalII – Clinical informationa.Indication:The reason for referral is the justification for performing the study and should indicate the clinical question the study is designed to answerb.Other relevant historyb-1. State the most recent serum creatinine values and date. Otherwise state there is no recent creatinine available.b-2. When the renography is performed using either furosemide or captopril, list current medications especially those which may disturb renal hemodynamics and renal transit time (such as diuretic, angiotensin-converting enzyme inhibitor or angiotensin-receptor blocker, calcium blocker, non-steroidal anti-inflammatory drug) and interfere in the test interpretation). Similarly indicate a sodium dietary restriction. b-3. Summarize relevant results of recent nephrourologic imaging procedures (CT, US, MRI, etc.) or radionuclide renal test, and date of procedure.b-4. Summarize any relevant urological procedures (pyeloplasty, stent placement or removal, percutaneous nephrostomy, lithotripsy…) and date of procedure.III – Procedure descriptiona.Specify any additional hydration in the department (oral, intravenous, type of hydration, volume and timing relative to tracer injection).a.RadiopharmaceuticalState the name of radiopharmaceutical and type of tracer: Glomerular filtration tracer, 99mTc- diethylenetriaminepentaacetic acid (DTPA)Tubular secretion tracer, 99mTc mercaptoacetyltriglycine (mertiatide) (MAG3), 99mTc L,L - ethylenedicysteine (EC), 131I- or 123I- orthoiodohippurate (OIH), (not in general use)99mTc-(CO3) tricarbonylnitriloacetic acid (NTA, not commercially available.) retention Retention tracer, 99mTc-dimercaptosuccinic acid (DMSA) Glomerular filtration and cortical retention tracer, 99mTc-glucoheptonate (GH)c.Indicate administered activity (“dose”) in MBq and . Consider :estimation of the effective dose as expressed in mSv. Theand the equivalence in terms of percentage of the yearly natural radiation or effective dose of thorax-abdomen-pelvis CT is recommended.d.Indicate the route of administration and, eventually, the poor qualityand quality of the IV bolus injection. with extravasation. e.Indicate other drugs used, such as furosemide (see guideline on obstructive uropathy) or captopril (see guideline on renovascular hypertension). Indicate name, dose, route of administration, and delay (min) between radiopharmaceutical administration and image acquisition (e.g., F-15, F0, F+20, captopril + 60, …).f.Indicate whether the patient could have voided immediately before the image acquisition or not (especially for renography). Indicate the patient position during acquisition (e.g., supine)h.Indicate the timing of image acquisition relative to the radiopharmaceutical administration (especially for renal cortical imaging).Describe the imaging procedureDynamic acquisition: number of stages (e.g., vascular, renal, furosemide post-injection, post-micturition,…), frame time (in seconds), duration (in minutes), and incidence views (e.g., posterior for renography, anterior for transplant evaluation). Post void acquisition after an upright posture for a few minutes (diuresis renography).Image the injection site if either a camera-based clearance or a quantitative kidney uptake (as expressed in percentage of the injected activity) measurement if performed.Static acquisition: delay between DMSA injection and image acquisition, and either frame time and incidences positions (e.g., posterior and oblique’s) or SPECT.j.Measure the voided volume and note the time of voiding to estimate the urine flow rate (diuresis or captopril renography).k.Indicate any side effect or complication (e.g., flank pain during diuresis renography or blood pressure drop after captopril,…) and related treatment.Processing:State Describe background and renal (whole-kidney) regions of interest (ROIs) and method of relative renal uptake measurement and transit/drainage parameter calculation. State Describe additional ROIs (e.g., parenchymal, pelvic) and other quantitative parameters of uptake and transit/drainage.Description of findings Indicate the quality of the study (e.g., dose extravasation, patient motion,..)State the configuration of the kidneys (i.e., sizes, shapes, locations, defects, symmetry…) RenographyDescribe the image series (e.g., symmetrical and prompt uptake, rapid excretion, no significant retention in the collecting system…) and, if abnormal, renograms (e.g., vascular first-pass pattern, plateauing curve,…) Specify quantitative parametersRelative uptake of the right and left kidneys, expressed as percentages of the total uptake and the normal range.Transit parameters of transit/drainage and their normal rangesVoided volume, urine flow rate and residual urine volume, when appropriate Cortical renal imagingDescribe the shapes, contours, uptake homogeneity, column de Bertin visualization,…Specify the relative uptake of the right and left kidneys, expressed as percentages of the total uptake and the normal range.Impression and result display on hard copiesName of the patient, date of birth and date of the testRadiopharmaceutical and diuresis or captopril renography when appropriateRelative renal function as expressed in percentages and normal rangeTransit parameters (one or two at the most) with their normal rangesA short series of summed images representative of the different phases of the renography. Gray or color scale can be used. For cortical renal imaging using film rather paper print is recommended.Labelled ROIs on a summed image Right and left background-corrected renograms, identified by color or line structure, displayed on the same diagram. The renogram curves should express in counts/sec and scaled on the y-axis on the higher peak ments and conclusionIndicate any study limitation, patient symptom or side-effect Recall the indication and specific clinical questionState in an as clear (e.g., avoid “…consistent with…”) and concise a statement as possible either the suspected diagnosis or the answer to the asked questionindication for the test.Differential diagnosis, if appropriateRecommendations for further diagnostic procedures, if appropriateName and reference of the nuclear medicine physician responsible of the test.Requesting physician, and other health care providers such as the primary care physician, if appropriateVIII. EQUIPMENT SPECIFICATIONS IX QUALITY CONTROL AND IMPROVEMENTBefore processing, image data of dynamic renal scintigraphy should be first checked for sufficient number of counts (signal-to-noise ratio), extravasation, appearance of activity in the heart, position of the patient and of examined organs in the field of view and for motion. A simple means for the quality control is to run the study in a cine mode. Patient movement, renal uptake of the tracer, transit from parenchyma to pelvis as well as drainage of the collecting systems is thus easily noted [Gordon 2011].Visual assessment of the images can be completed by simple aids. It is assumed that in a normal kidney, a peak renal count rate after background subtraction of approximately 200-250 cps will result in a renogram requiring no or little smoothing prior to interpretation and estimation of relative function [Cosgriff 1992, Prigent 1999]. For time-activity curves from the kidney and background ROIs, a formula for the number n of passes of a (1-2-1) filter, subject to a minimum of two, has been recommended by Fleming [Fleming 2006]Required number of counts also depends on type of analysis to be done. More sophisticated methods may need faster frame rate and higher number of counts than qualitative assessment of the study or simple measurement of relative renal function. Flow (perfusion) study requires higher injected activity to reach sufficient number of counts in the images recorded with the fast frame rate. Improving sensitivity of modern gamma cameras allows for sufficient number of counts to be achieved with lower administered activity. However, quantitative studies to derive new minimum activity levels in both children and adults remain to be done.Some quantitative methods require specifying time zero from which other time intervals can be measured. Of several alternatives, most authors recommend to use peak time of the heart ROI curve because some analytical methods assume monotonously decreasing (input) heart curve. The peak of the heart ROI curve thus should be visible on the curve to make sure that data acquisition started before the peak. In other words, the raw curve should not start at its maximum in the first frame because then it is not clear whether it is the proper maximum or a point already on the descending part of the curve in case the study was started too late. Before processing, the images or the curve points before the peak of the heart curve should be deleted. In a similar way, renal curves should start from zero or nearly zero counts. It is a cross-check in case the heart ROI curve peaks in the first recorded frame.Extravasation at the site of the injection may give rise to difficulties in data processing and may lead to incorrect interpretation of the study as the shape of ROI curves may be deviated affected [Gordon 2011]. Assessment of total renal function requires measurement of count rate in the kidneys that is often related to injected counts and expressed as its fraction. If part of administered activity is injected extravenously or it is delayed at the site of injection, the measurement is inaccurate. Some authors therefore recommend scanning the injection site after the study. If the count rate at the injection site exceeds 1-2 % of injected counts, calculation of total renal function should be avoidedomitted.Both kidneys should be at the center of the field of view that should also include both the heart and the bladder wherever it is possible with respect to the size of the patient. In many adults, a decision has to be made in advance what position of the field of view is preferred for a diagnosis in a specific patient, whether one including the heart or one including the urinary bladder.Motion can be detected either visually (checking that the kidneys remain within the renal ROIs during the first few minutes after injection) or using special software. Small motion can be usually well corrected by motion-correction software or simply compensated by drawing kidney ROIs large enough to encompass the motion [Cosgriff 1992, Prigent 1999]. Large and complex motion of the patient, motion of the kidneys due to deep breathing and other physiological movements, often of different size and direction on the left and right sides, and especially an intra-frame motion are difficult or impossible to correct properly with the tools routinely available. Therefore considerable effort should be made to avoid motion during data acquisition. Clear explanation of the procedure to adult patients and vacuum cushions or similar gentle immobilization aids for small children is often sufficient to avoid motion so that neither sedation nor anesthesia is usually required. In cases of extreme motion, it may be necessary to repeat the study.Most frequent errors- patient is fasting before examination- patient is not sufficiently hydrated before examination- urinary bladder is not voided emptied before examination- injected activity is not measured and recorded- injected activity is too low or too high- part of injected activity is administered extravenously- weight and height of the patient is not measured and recorded- times of activity measurement, injection, and start of the study are not recorded- the heart / urinary bladder (depending on the purpose of the study) are outside the field of view- motion of the patient is not prevented- motion of the patient is not recognized and corrected- data acquisition is started too late so that the peak of the heart ROI curve is missed- frame intervals in the uptake phase are too long (> 10 s)- the heart ROI is too looselarge- the kidney ROIs are too loose large or too tightsmall- background ROIs include part of the kidney, renal pelvis or the ureters- some values of the kidney ROI curve after background subtraction are negative- specified uptake interval starts too early- specified uptake interval ends too late- specified uptake interval includes the peak of the kidney curve- optimal position of uptake interval is not checked with both kidney curves- background counts are not subtracted- subtraction of vascular background is neglected or not performed properly- measurement of split renal function and other indices is performed only once- number of measurements, arithmetic mean value and its variance are not reported- conjugate (posterior and anterior) views are not checked for registration- geometric mean of conjugate views is not calculated pixel wise but with the kidney ROI sumsis improperly calculated- posterior view is not corrected for table attenuation- post-erect post-voiding images after dynamic renal study are not recordedImage data should be checked for- sufficient number of counts- extravasation- appearance of activity in the heart ROI- position of the patient- position of the examined organs in the FOV- motionItems to be especially considered in the measurement of kidney counts- definition of uptake interval- definition of ROIs- background subtraction- attenuation correction- scatter correctionX. SAFETY CONFECTION CONTROL AND PATIENT EDUCATIONS CONCERNSXI. RADIATION SAFETY IN IMAGINGAn SNM guideline on dosimetry is being developed. When approved and available this guideline will supersede the radiation dosimetry tables in individual guidelines. Approval for each guideline should be obtained from the EANM Dosimetry Committee during the guideline writing process. The values for the radiation dosimetry tables are usually readily available from the SNM MIRD committee, ICRP 54 and it addenda. The estimated radation doses for the procedures and agents discussed in this guideline are shown in the tables below:Table 1. Radiation Dosimetry in AdultsAdministered activitiesLargest radiation doseEffective doseRadiopharmaceuticalMBq min?MBq maxmCi min?mCi max?OrganmGy/MBqrad/mCi?mSv/MBqrem/mCi51Cr EDTA*3.7-3.70.1-0.1Bladder0.0240.08950.00200.008123I hippuran?3.7-14.80.1-0.4Bladder0.190.710.01200.045131I hippuran?1.295-1.2950.035-0.035Bladder0.923.430.05200.19699mTc DMSA*74-2222.0-6.0Kidney0.180.670.00880.03399mTc DTPA*185-3705.0-10.0Bladder0.0620.230.00490.01899mTc EC*185-3705.0-10.0Bladder0.0950.350.00630.02499mTc glucoheptonate# 370-55510.0-15.0Bladder0.0560.210.00900.03499mTc MAG3*185-3705.0-10.0Bladder0.110.410.00700.026?*Data are from (ICRP Publication 106. Radiation Dose to Patients from Radiopharmaceuticals - Addendum 3 to ICRP Publication 53. Ann. ICRP 38 (1-2), 2008)?Data are from (ICRP Publication 80. Radiation Dose to Patients from Radiopharmaceuticals (Addendum to ICRP Publication 53) Ann. ICRP 28 (3), 1998)#Data are from (Radiation Dose to Patients from Radiopharmaceuticals ICRP Publication 53 Ann. ICRP 18 (1-4), 1988.)?Table 2.?Dose to the fetus per unit activity administered to the mother (mGy/MBq)?Early3 months6 months9 months51Cr EDTA*3.4x1032.6x1031.3x1031.2x103123I Hippuran?3.1x1022.4x1028.4x1037.9x103131I Hippuran?6.4x1025.0x1021.9x1021.8x10299mTc DMSA?5.1x1034.7x1034.0x1033.4x10399mTc DTPA?1.2x1028.7x1034.1x1034.7x10399mTc EC*1.3x1029.7x1034.0x1033.8x10399mTc Glucoheptonate?1.2x1021.1x1025.3x1034.6x10399mTc MAG3?1.8x1021.4x1025.5x10-35.2x10-3?*No published data. Personal Communication, M Stabin, 2017?Russell JR and Stabin MG, Sparks RB and Watson EE. Radiation Absorbed Dose to the Embryo/Fetus from Radiopharmaceuticals. Health Phys 1997; 73(5):756-769XII. ACKNOWLEDGMENTSThe authors acknowledge the members of the EANM (Name) Committee, of the European Society of (Name), of the EANM Executive Committee, and of the SNMMI Committee on Guidelines for their contributions to this manuscript.The Committee on SNMMI Guidelines consists of the following individuals:Kevin J. Donohoe, MD (Chair) (Beth Israel Deaconess Medical Center, Boston, MA); Sue Abreu, MD (Sue Abreu Consulting, Nichols Hills, OK);Helena Balon, MD (Beaumont Health System, Royal Oak, MI); Twyla Bartel, DO (UAMS, Little Rock, AR); Paul E. Christian, CNMT, BS, PET (Huntsman Cancer Institute, University of Utah, Salt Lake City, UT); Dominique Delbeke, MD (Vanderbilt University Medical Center, Nashville, TN); VaskenDilsizian, MD (University of Maryland Medical Center, Baltimore, MD); Kent Friedman, MD (NYU School of Medicine, New York, NY); James R. Galt, PhD (Emory University Hospital, Atlanta, GA); Jay A. Harolds, MD (OUHSC-Department of Radiological Science, Edmond, OK); Aaron Jessop, MD (UT MD Anderson Cancer Center, Houston, TX); David H. Lewis, MD (Harborview Medical Center, Seattle, WA); J. Anthony Parker, MD, PhD (Beth Israel Deaconess Medical Center, Boston, MA); James A. Ponto, RPh, BCNP (University of Iowa, Iowa City, IA); Lynne T. Roy, CNMT (Cedars/Sinai Medical Center, Los Angeles, CA); Schoder, MD (Memorial Sloan-Kettering Cancer Center, New York, NY); Barry L. Shulkin, MD, MBA (St. Jude Children’s Research Hospital, Memphis, TN); Michael G. Stabin, PhD (Vanderbilt University, Nashville, TN); Mark Tulchinsky, MD (Milton S. Hershey Med Center, Hershey, PA)The EANM Executive Committee consists of the following individuals:Fred Verzijlbergen, MD, PhD (Erasmus MC Centreal Location, Rotterdam, Netherlands); Arturo Chiti, MD (IstitutoClinicoHumanitas, RozzanoMi, Italy); SavvasFrangos, MD (Bank of CyprusXIII. APPROVALReferencesReferences1.Blaufox, MD. (1991) Procedures of choice in renal nuclear medicine, J Nucl Med 32:1301-13092.Blaufox MD, Aurell M, Bubeck B, Fommei E, Piepsz A, Russell C, Taylor A, Thomsen HS, Volterrani D. (1996) Report of the Radionuclides in Nephrourology Committee on renal clearance. J Nucl Med. Nov;37(11):1883-90.3. Blaufox, MD. Editorial Comments: Renal background correction and measurement of split renal function: The challenge. Eur J Nucl Med.Mol Imaging, 43:548-549, 201643.Bocher M, Shrem Y, Tappiser A, Klein M, Schechter D, Taylor A Jr, Chisin R. Tc-99m mercaptoacetyltriglycine clearance, comparison of camera-assisted methods. ClinNucl Med 2001;26(9):745-750.54.Boubaker A, Prior JO, Meuwly JY, Bischof-Delaloye A. Radionuclide investigations of the urinary tract in the era of multimodality imaging. J Nucl Med 2006;47:1819-1836.65.Boyd RE, Robson J, Hunt FC, Sorby PJ, Murray IP, McKay WJ. 99mTc gluconate complexes for renal scintigraphy. Br J Radiol. 1973 Aug;46(548):604-12.76.Bubeck B, Brandau W, Eisenhurt M, Weidenhammer K, Georgi P. (1987) The tubular extraction rate (TER) of Tc-99m MAG3: A new quantitative parameter for renal parameter of renal function. Nucl Compact 18:260-26787.Caglar M, Gedik GK, Karabulut E. Differential renal function estimation by dynamic renal scintigraphy: influence of background definition and radiopharmaceutical. Nucl Med Commun 2008;29:1002-1005.98.Chantler C, Barratt TM. (1972) Estimation of glomerular ?ltration rate from plasma clearance of 51Cr-edetic acid. Arch Dis Child 47:613-617 109.Cosgriff PS, Lawson RS, Nimmon CC. Towards standardization in gamma camera renography. Nucl Med Commun 1992;13:580-585.110.Delpassand ES, Homayoon K, Madden T, Mathai M, Podoloff DA. (2000) Determination of glomerular filtration rate using a dual-detector gamma camera and the geometric mean of renal activity: correlation with the Tc-99m DTPA plasma clearance method. ClinNucl Med. 25(4):258-62.112.De Palma D, Manzoni GA. Different imaging strategies in febrile urinary tract infection in childhood. What, when, why? Pediatr Rad April 2013, 43, (4), 436-443 132.De Palma D, Santos AI: Renal radionuclide imaging: an evergreen forty years old. Klin P?diatr 2014 mar 25.143.Dubovsky EV, Russell CD, Bischof-Delaloye A, Bubeck B, Chaiwatanarat T, Hilson AJ, Rutland M, Oei HY, Sfakianakis GN, Taylor A Jr. (1999) Report of the Radionuclides in Nephrourology Committee for evaluation of transplanted kidney (review of techniques). SeminNucl Med. 29(2):175-88.154.Esteves FP, Halkar RK, Issa MM, Grant S, Taylor A. Comparison of camera-based 99mTc-MAG3 and 24-hour creatinine clearances for evaluation of kidney function. AJR 2006;187:W316-W319.165.Esteves FP, Taylor A, Manatunga A Folks RD, Krishnan M, Garcia EV. 99mTc-MAG3 renography: normal values for MAG3 clearance and curve parameters, excretory parameters, and residual urine volume. AJR 2006;187:W610-W617.17. Fine EJ, Blaufox MD On Behalf of the Albert Einstein College of Medicine/Cornell University Medical Center Collaborative Hypertension Group: The Einstein/Cornell Collaborative Protocol to Assess Efficacy and Methodology in Captopril Scintirenography. Am J. Hypertens 4:716S-720S, 1991 186.Fleming JS. A technique for analysis of geometric mean renography. Nucl Med Commun 2006;27:701-708.197.Fritzberg AR, Kasina S, Eshima D, Johnson DL. (1986) Synthesis and biological evaluation of Tc-99m MAG3 as a hippuran replacement. J Nucl Med 27: 111-1162018.Fommei E, Ghione S, Hilson AJW, et al: Captopril radionuclide test in renovascular hypertension: A European multicentre study. Eur J Nucl Med 20:617-623, 1993.2119.Gates GF. (1982) Glomerular filtration rate: estimation from fractional renal accumulation of 99mTc-DTPA (stannous). AJR Am J Roentgenol. 138(3):565-570220.Gordon I; Piepsz A; Sixt R (2011): Guidelines for standard and diuretic renogram in children: Eur J Nucl Med Mol Imaging DOI 10.1007/s00259-011-1811-3231.Hauser W, Atkins H. L, Nelson K. G, Richards P: Technetium-99m DTPA: A New Radiopharmaceutical for Brain and Kidney Scanning, Radiology March 1970 Vol 94, Issue 3242.Hilson AJ, Maisey MN, Brown CB, Ogg CS, Bewick MS.(1978) Dynamic renal transplant imaging with Tc-99m DTPA (Sn) supplemented by a transplant perfusion index in the management of renal transplants. J Nucl Med. 19(9):994-1000.253.International Commission on Radiation Protection.ICRP publication 80, Absorbed doses.Radiation dose to patients from radiopharmaceuticals. Addendum 2 to ICRP Publication. Oxford: Pergamon Press; 1998.264.Itoh K. (2003) Comparison of methods for determination of glomerular ?ltration rate: Tc-99m-DTPA renography, predicted creatinine clearance method and plasma sample method. Annals of Nuclear Medicine 17(7): 561–565275.Kirchner PT, Goldman MH, Leapman SB, Kiepfer RF. (1978) Clinical application of the kidney to aortic blood flow index (K/A ratio). ContribNephrol. 11:120-6.286.Lezaic L, Hodolic M, Fettich J, Grmek M, Milcinski M. Reproducibility of 99mTc-mercaptoacetyltriglycine renography: population comparison. Nucl Med Commun 2008;29:695-704.297.Li Y, Russell CD, Palmer-Lawrence J, Dubovsky EV. (1994) Quantitation of renal parenchymal retention of technetium-99m-MAG3 in renal transplants. J Nucl Med. 35(5):846-50.2830.Lin TH, Khentigan A, Winchell HS. A 99mTc-chelate substitute for organoradiomercurial renal agents. J Nucl Med. 1974 Jan;15(1):34-5.2931.Lythgoe MF, Gordon I; Khader Z, Smith T, Anderson PJ. Assessment of various parameters in the estimation of differential renal function using technetium-99mmercaptoaccetyltriglycine. Eur J Nucl Med 1999; 26:155-162320.Majd M, Potter BM, Guzzetta PC, Ruley EJ. (1983) Effect of captopril on efficacy of renal scintigraphy in detection of renal artery stenosis (abstract). J Nucl Med 24: 23331.Müller-Suur R, Müller-Suur C. (1989) Glomerular filtration and tubular secretion of MAG-3 in the rat kidney. J Nucl Med. 30(12):1986-91.342.O’Reilly PH, Testa HJ, Lawson RS, Farrar DJ, Edwards EC. (1978) Diuresis renography in equivocal urinary tract obstruction. Br J Urol 50: 76-80335.O’Reilly PH. Diuresis renography: recent advances and recommended protocols. Br J URol 1992;69:113-120.364.O’Reilly P, Britton K, et al. Consensus report on diuresis renography for investigating the dilated upper urinary tract. J Nucl Med 1996; 37:1872-1876.375.Piepsz A. Dobbeleir A, Ham HR: Effect of background correction on separate technetium-99m-DTPA renal clearance. J Nucl Med 31:430-435, 1990.386.Piepsz A, Colarinha P, Gordon I, Hahn K, Olivier P, Roca I, Sixt R, van Velzen J; Guidelines for 99mTc-DMSA scintigraphy in children.Eur J Nucl Med. 2001 Mar;28(3):BP37-41. Revision 2010 on line397.Prigent A, Cosgriff P, Gates GF, Granerus G, Fine EJ, Itoh K, Peters M, Piepsz A, Rehling M, Rutland M, Taylor A Jr. (1999) Consensus report on quality control of quantitative measurements of renal function obtained from the renogram: International Consensus Committee from the Scientific Committee of Radionuclides in Nephrourology. SeminNucl Med. 29(2):146-59.3840.Prigent A and Chaumet-Riffaud P. 2014 Clinical problems in renovasular disease and the role of nuclear medicine. SemNucl Med 44: 110-1223941.Rado JP, Bano C, Tako J. (1968) Radioisotope renography during furosemide (Lasix) diuresis. Nucl Med Commun 7:212-221420.Russell CD, Dubovsky EV. (1999) Reproducibility of Single-Sample Clearance of 99mTc-Mercaptoacetyltriglycine and 131I-Orthoiodohippurate. J Nucl Med 40:1122-1124431.Rutland MD1983. Glomerular filtration rate using 99mTc DTPA and a gamma camera. Eur J Nucl Med 4: 425-433442.Samal M, Ptacnik V, Jiskrova H, Kotalova D, Kubinyi J, Rysava R, Tesar V. Improved accuracy of renal clearance measured by gamma camera. Eur J Nucl Med Mol Imaging 2011;38(Suppl. 2):S408 453.Schlegel JU, Hamway SA. (1976) Individual renal plasma flow determination in 2 minutes. J Urol. 116(3):282-5.464.Sfakianakis GN, Sfakianikis ED: Nuclear medicine in pediatric urology. J Nucl Med 29:1287-1300, 1988.475.Stabin M, Taylor A, Eshima D, et al: Radiation dosimetry for technetium-99m-DTPA, and iodine-131-OIH based on human biodistribution studies. J Nucl Med 33:33-40, 1992.486.Stacy BD, Thorburn GD. Chromium-51 ethylenediaminetetraacetate for estimation of globerular filtration rate. Science. 1966 May 20;152(3725):1076-7.497.Tauxe WN, Dubovsky EV, Kidd T Jr, Diaz F, (1982) Smith LR. New formulas for the calculation of effective renal plasma flow. Eur J Nucl Med. 7(2):51-4.4850.Taylor A, Nally J, Aurell M, Blaufox D, Dondi M, Dubovsky E, Fine E, Fommei E, Geyskes G, Granerus G, Kahn D, Morton K, Oei HY, Russell C, Sfakianakis G, Fletcher J. (1996) Consensus report on ACE inhibitor renography for detecting renovascular hypertension. Radionuclides in Nephrourology Group. Consensus Group on ACEI Renography. J Nucl Med. 37(11):1876-82.4951.Taylor AT Jr, Fletcher JW, Nally JV Jr, Blaufox MD, Dubovsky EV, Fine EJ, Kahn D, Morton KA, Russell CD, Sfakianakis GN, Aurell M, Dondi M, Fommei E, Geyskes G, Granerus G, Oei HY (1998) Procedure guideline for diagnosis of renovascular hypertension. Society of Nuclear Medicine. J Nucl Med. 39(7):1297-302520.Taylor A Jr, Corrigan PL, Galt J, Garcia EV, Folks R, Jones M, Mantunga A, Eshima D. Measuring technetium-99m-MAG3 clearance with an improved camera-based method. J Nucl Med 1995;36:1689-1695.531.Taylor A Jr, Mantunga A, Morton K, Reese L, Prato FS, Greenberg E, Folks R, Kemp BJ, Jones ME, Corrigan PE, Galt J, Eshima L. Multicenter trial validation of a camera-based method to measure Tc-99m mercaptoacetyltriglycine, or Tc-99m MAG3 clearance. Radiology 1997;204:47-54.542.Taylor A. (2006) ACE inhibition renography in the evaluation of suspected renovascular hypertension. In: Prigent A, Piepsz A (eds) Functional imaging in nephrourology. Taylor and Francis, London, 2006 pp 149 -164553.Taylor AT, Blaufox MD, De Palma D, Dubovsky EV, Erbas B? Eskild-Jensen A, Fr?ki?r J, Issa MM, Piepsz A, Prigent A.Guidance Document for Structured Reporting of Diuresis Renography. SeminNucl Med 42:41-48, 2012564.Tubis M, Posnick E, Nordyke RA. (1960) Preparation and use of I-131 labeled sodium iodohippurate in kidney function test. Proc Soc Exp Biol Med 103: 497-49857. Yee CA, Lee HB, Blaufox MD DMSA renal uptake: influence of biochemical and physiologic factors. J Nucl Med. 1981 Dec;22(12):1054-8.585.Willis KW, Martinez DA, Hedley-Whyte ET, Davis MA, Judy PF, Treves S. (1977) Renal localization of 99mTc-stannous glucophetonate and 99mTc-stannous dimercaptosuccinate in the rat by frozen section autoradiography. The efficiency and resolution of technetium-99m. Radiat Res. 69(3):475-88.Additional Sugested ReadingReferences not utilized:Brink A, Samal M, Mann MD. The reproducibility of measurements of differential renal function in paediatric 99mTc-MAG3 renography. Nucl Med Commun 2012a; 33:824-831.Brink A, Samal M, Mann MD. Reply to: The reproducibility of measurements of differential renal function in paediatric 99mTc-MAG3 renography: Is this correct? Reply to the Letter to the Editor. Nucl Med Commun 2012b;33:1311-1312 (DOI: 10.1097/MNM.0b013e3283594554).Brolin G, SjoegrenGleisner K, Ljungberg M. Dynamic 99mTc-MAG3 renography: images for quality control obtained by combining pharmacokinetic modelling, an anthropomorphic computer phantom and Monte Carlo simulated scintillation camera imaging. Phys Med Biol 2013;58:3145-3161,doi:10.1088/0031-9155/58/10/3145.BusemanSokole E, Plachcinska A, Britten A. Routine quality control recommendations for nuclear medicine instrumentation. Eur J Nucl Med Mol Imaging 2010;37:662-671, DOI 10.1007/s00259-009-1347-y.Carlsen O. The gamma camera as an absolute measurement device: determination of glomerular filtration rate in 99mTc-DTPA renography using a dual head gamma camera. Nucl Med Commun 2004;25:1021-1029.Cosgriff PS (editor). Quality assurance of nuclear medicine software. COST B2 final report. EUR 17916 EN. European Communities, Directorate-General Science, Research and Development, Luxembourg, 1997 (ISBN 92-828-1501-3).Dissmann T, Gotzen R, Neuber K, Offermann B, Schwab M. Das Erythrocyten- und Plasmavolumensowie die Relation zwischenK?rperh?matokrit und ven?senH?matokrit in verschiedenStadien der essentiellen und beirenovascul?rerHypertonie. KlinWochenschr 1971;49:915-927 (in German).Fleming JS. A technique for the absolute measurement of activity using a gamma camera and computer. Phys Med Biol 1979;24(1):176-180.Fleming JS. Estimation of organ input function and plasma clearance from the cardiac curve in dynamic scintigraphy. Eur J Nucl Med 1992;19:248-253.Fleming JS. Quantitative measurements from gamma camera images. In Greaves CD (ed), Mathematical Techniques in Nuclear Medicine (IPEM Report 100), Institute of Physics and Engineering in Medicine, York, 2011, pp 22 - 74. Goris M. Nuclear medicine applications and their mathematical basis. World Scientific Books, 2011 (ISBN 981-283-734-5).Heikkinen JO. New automated physical phantom for renography. J Nucl Med 2004;45(3):495-499.Inoue Y, Yoshikawa K, Suzuki T, Katayama N, Yokoyama I, Kohsaka T, Tsukune Y, Ohtomo K. Attenuation correction in evaluating renal function in children and adults by a camera-based method. J Nucl Med 2000;41:823-829.International Committee for Standardization in Haematology. Recommended methods for measurement of red-cell and plasma volume. J Nucl Med 1980;21:793-800.King M, Farncombe T. An overview of attenuation and scatter correction of planar and SPECT data for dosimetry studies. Cancer BiotherRadiopharm 2003; 18(2):181-190.Kojima A, Ohyama Y, Tomiguchi S, Kira M, Matsumoto M, Takahashi M, Motomura N, Ichihara T. Quantitative planar imaging method for measurement of renal activity by using a conjugate-emission image and transmission data. Med Phys 2000;27(3):608-615.Linderkamp O, Mader T, Butenandt O, Riegel KP. Plasma volume estimation in severely ill infants and children using a simplified evans blue method. Eur J Pediat 1977;125:135-141.Linderkamp O. Versmond HT, Riegel KP, Betke K. Estimation and prediction of blood volume in infants and children. Eur J Pediat 1977;125:227-234.Lythgoe MF, Gradwell MJ, Evans K, Gordon I. Estimation and relevance of depth correction in paediatric renal studies. Eur J Nucl Med 1998;25:115-119.Madsen CJ, Moller ML, Zerahn B, Fynbo C, Jensen JJ. Determination of kidney function with 99mTc-DTPA renography using a dual-head camera. Nucl Med Commun 2013;34:322-327.Nimmon CC, Samal M, Britton KE. Elimination of the influence of total renal function on renal output efficiency and normalized residual activity. J Nucl Med 2004;45:587-593.Nimmon CC, Samal M, Fleming JS. Subtraction of extravascular background from the cardiac curve in DTPA and MAG3 renography using a constrained deconvolution technique. Eur J Nucl Med Mol Imaging 2007;34(Suppl 2):S126(abstract 35).Pearson TC, Guthrie DL, Simpson J, Chinn S, Barosi G, Ferrant A, Lewis SM, Najean Y. Interpretation of measured red cell mass and plasma volume in adults: Expert Panel on Radionuclides of the International Council for Standardization in Haematology. Brit J Haematol 1995;89:748-756.Peters AM, Gordon I, Evans K, Todd-Pokropek A. Background in 99Tcm-DTPA renography evaluated by the impact of its components on individual kidney glomerular filtration rate. Nucl Med Commun 1988;9:545-552.Rehling M, Moller ML, Lund JO, Jensen KB, Thamdrup B, Trap-Jensen J. 99mTc-DTPA gamma-camera renography: normal values and rapid determination of single-kidney glomerular filtration rate. Eur J Nucl Med 1985;11:1-6.Rutland MD. Glomerular filtration rate without blood sampling. Nucl Med Commun 1983;4:425-433.Rutland M, Que L, Hassan IM. "FUR" - one size suits all. Eur J Nucl Med Mol Imaging 2000;27:1708-1713.Samal M, Bergmann H. Hybrid phantoms for testing the measurement of regional dynamics in dynamic renal scintigraphy. Nucl Med Commun 1998;19:161-171.Samal M, Kubinyi J, Kotalova D, Steyerova P, Chroustova D, Ptacnik V, Danes J. Prediction of kidney depth and body thickness in renal scintigraphy. J Nucl Med 2009a, Meeting Abstracts; 50:1402.Samal M, Kubinyi J, Komarek A, Kotalova D, Steyerova P, Chroustova D, Ptacnik V. Improved prediction of kidney depth and body thickness in renal scintigraphy. Eur J Nucl Med Mol Imaging 2009b; 36(Suppl.2):S192 (abstract OP182).Samal M, Ptacnik V, Skibova D, Jiskrova H, Kubinyi J. Fractional rate as unjustly neglected approach to gamma-camera of renal and plasma clearance. Eur J Nucl Med Mol Imaging 2012;39(Suppl. 2):S601, (abstract P1094).Samal M, Valousek J. Clinically documented data set of dynamic renal scintigraphy for clinical audits and quality assurance of nuclear medicine software. Eur J Nucl Med 2012;39(Suppl. 2):S170-S171 (abstract OP087).Samal M, Ptacnik V, Skibova D, Jiskrova H, Kubinyi J. Quality assurance of gamma-camera measurement of 99mTc-MAG3 renal clearance. Eur J Nucl Med 2013; 40(Suppl. 2):S187 (abstract OP409), DOI 10.1007/s00259-013-2535-3.Taylor A, Lewis C, Giacometti A, Hall EC, Barefield KP. Improved formulas for the estimation of renal depth in adults. J Nucl Med 1993;34:1766-1769.Taylor A Jr. Formulas to estimate renal depth in adults. Letter to the Editor. J Nucl Med 1994;35(12):2054-2055.Tonnesen KH, Munck O, Hald T, Mogensen P, Wolf H. Influence on the renogram of variation on skin to kidney distance and the clinical importance thereof. In: Radionuclides in Nephrology: Proceedings of the 3rd International Symposium, Berlin, April 1974. ZumWinkel K, Blaufox MD, Funck-Bretano J-L, eds. Thieme, Stuttgarg, 1975.Wesolowski CA, Puetter RC, Ling L, Babyn PS. Tikhonov adaptively regularized gamma variate fitting to assess plasma clearance of inert renal markers. J PharmacokinetPharmacodyn 2010;37:435-474 Consensus report on quality control of quantitative measurements of renal function obtained from the renogram: International Consensus Committee from the Scientific Committee of Radionuclides in Nephrourology. Prigent A, Cosgriff P, Gtaes GF, Granerus G, Fine EJ, Itoh K, Peters M, Piepsz A, Rehling M, Rutland M and Taylor A Jr.SeminNucl Med 1999, 29: 146-159Summary and Concluding RemarksOncology Center, Strovolos, Nicosia Cyprus); Jure Fettich, MD (University Medical Centre Ljubljana, Ljubljana, Slovenia); Bernd J. Krause, MD, PhD (Universit?tsklinikum Rostock, Rostock, Germany); Dominique Le Guludec, PhD (Hopital Bichat, Paris, France); WimOyen, MD, PhD (Radboud University Medical Centre, Numegen, Netherlands)1.ACR-SPR Practice Guideline for the performance of renal scintigraphy2.Technologist Guide – Best Practice in Nuclear Medicine, Part 2 – EANM 20073.Technologist Guide – Dynamic Renal Imaging – EANM 20094.Christian P, Bernier, D, Langan J, Nuclear Medicine and PET - Technology and Technics. 5th edition Mosby, chapter 17. Pp 475-489. Which Year?2 - The SNM procedure guideline for general imaging 6.0 (Revised 2010)4 - ACR–SPR Practice guideline for the performance of renal scintigraphy (Revised 2013) 5 - AndewT.TaylorRadionuclides in Nephrourology, Part 1: Radiopharmaceuticals, Quality control, and Quantitative indices. J Nucl Med 2014; 55: 1-8.Amesur P, Castronuovo JJ, Chandramouly B. (1988) Infected cyst localization with gallium SPECT imaging in polycystic kidney disease. ClinNucl Med. 13(1):35-7.Anger H. Scintillation camera. (1958) Rev SciInstrum, 29:27Anger H. Scintillation camera with multichannel collimators. (1964) J Nucl Med, 5:515Arnello F, Ham HR, Tondeur M, Piepsz A. (1999) Overall and single-kidney clearance in children with urinary tract infection and damaged kidneys. J Nucl Med. 40(1):52-5.Budinger TF. PET instrumentation: what are the limits? (1998) SeminNucl Med. 28(3):247-67.Brown SCW, Upsdell SM, O’Reilly PH. (1992) The importance of renal function in the interpretation of diuresis renography. Br J Urol 69(2): 121-125Monsour M, Azmy AF. MacKenzie JR. (1987) Renal scarring secondary to vesicoureteric reflux: critical assessment and new grading. Brit J Urol. 60: 320-324Tsang V, Lui S, Hilson A, Moorhead J, Fernando O, Sweny P.(1989) Gallium-67 scintigraphy in the detection of infected polycystic kidneys in renal transplant recipients. Nucl Med Commun. 10(3):167-70.Itoh K, Yamashita T, Tsukamoto E, Nonomura K, Furudate M, Koyanag T. (1995) Qualitative and quantitative evaluation of renal parenchymal damage by 99mTC-DMSA planar and SPECT scintigraphy. Annals of Nuclear Medicine Vol. 9, No.1, 23-28Bair HJ, Becker W, Schott G, Kühn RH, Wolf F. (1995) Is there still a need for Tc-99m DMSA renal imaging? ClinNucl Med. 20(1):18-21.Blaufox MD, Frohmuller HG, Campbell JC, Utz DC, Orvis AL, Owen CA Jr. (1963) A simplified method of estimating renal function with iodohippurate 1-131. J Surg Res 3:I22-125.Buckley, JC; McAninch, JW. (2011) Revision of Current American Association for the Surgery of Trauma Renal Injury Grading System. Journal of Trauma. 70(1):35-37Carlsen O. (2004) The gamma camera as an absolute measurement device: determination of glomerular filtration rate in 99mTc-DTPA renography using a dual head gamma camera. Nucl Med Commun. 25(10):1021-9.Campos A, Kim Y, Miller K, S Mauer M, Loken MK, Michael AF. (1982) Radionuclide Studies of the Kidney in Children with Hemolytic-Uremic Syndrome. Radiology 145(3):811-3.22.Chachati A, Meyers A, Gordon JP, et al: Rapid method for the measurement of differential renal function: Validation. J Nucl Med 28:829-836, 1987.Chen CC, Hoffer PB, Vahjen G, et al: Patients at high risk for renal artery stenosis: A simple method of renal scintigraphic analysis with Tc-99m DTPA and captopril. Radiology 176:365-370, 1990.Choong KKL, Gruenewald SM, Hodson EM, et al: Volume expanded diuretic renography in the postnatal assessment of suspected uretero-pelvic junction obstruction. J Nucl Med 33:2094-2098, 1992.Christensen AB, Groth S; 1986. Determination of 99mTc DTPA clearance by a simple plasma sample method. ClinPhysiol 6: 579-588Conway JJ: The principles and technical aspects of diuresis renography. J Nucl Med Technol 17:208-214, 1989.17.Dey HM, Hoffer PB, Lerner E, et al: Quantitative analysis of the technetium-99m-DTPA captopril renogram: Contribution of washout parameters to the diagnosis of renal artery stenosis. J Nucl Med 34:1416-1419, 1993.Djakovic N, Plas E, Martínez-Pi?eiro L, Lynch Th, Mor Y, Santucci RA, Serafetinidis E, Turkeri LN, Hohenfellner M. (2009) European Association of Urology (EAU) Guidelines on urological trauma. 2009 Mar. p. 6-30. V, Ling BN, Campbell WG, et al: Comparison of fine-needle aspiration biopsy, doppler ultrasound, and radionuclide scintigraphy in the diagnosis of acute allograft dysfunction in renal transplant recipients: Sensitivity, specificity, and cost analysis. Nephron 63:263-272, 1993.14.Dondi M, Fanti S, Fabritiis AD, et al: Prognostic value of captopril renal scintigraphy in renovascular hypertension. J Nucl Med 33:2040-2044, 1992.15.Dondi M, Franchi R, Levorato M, et al: Evaluation of hypertensive patients by means of captopril enhanced renal scintigraphy with technetium-99m DTPA. J Nucl Med 30:615-621, 1989.Fisher M, Veall N. (1975) Glomerular filtration rate estimation based on a single blood sample. Br Mud J 2:542.Goates JJ, Morton KA, Wooten WW, et al: Comparison of methods for calculating glomerular filtration rate: Technetium-99m-DTPA scintigraphic analysis, protein-free and whole-plasma clearance of technetium-99m-DTPA and iodine-125-iothalamate clearance. J Nucl Med 31:424-429, 1990.Goldfarb CR, Schoeneman M, Ongseng F, Finestone H. (1990) Scintigraphy of renal trauma. Radiology 174:896-897.Halkar R, Taylor A, Manatunga A, Issa MM, Myrick SE, Grant S, and Shenvi NV. (2007) Monitoring Renal Function: A Prospective Study Comparing the Camera-Based Tc-99m MAG3 Clearance and Creatinine Clearance. Urology. 69(3): 426–430.Ham HR, Piepsz A. (1991) Estimation of glomerular filtration rate in infants and children using a simple plasma sample method. J Nucl Med 32:1294-1297.10.Howman-Giles R, Uren R, Roy LP, et al: Volume expansion diuretic renal scan in urinary tract obstruction. J Nucl Med 28:824-828, 1987.udenhofer MS, Pichler BJ, Cherry SR. (2005) Evaluation of high performance data acquisition boards for simultaneous sampling of fast signals from PET detectors。 Phys Med Biol. 7;50(1):29-44.Juillard L, Janier MF, Fouque D, Lionnet M, Le Bars D, Cinotti L, Barthez P, Gharib C, Laville M. (2000) Renal blood flow measurement by positron emission tomography using 15O-labeled water. Kidney Int. 57(6):2511-8.4.Kass EJ, Fink-Bennett D: Contemporary techniques for the radioisotopic evaluation of the dilated urinary tract. UrolClin N Am 17:273-289, 1990.Killion D, Nitzsche E, Choi Y, Schelbert H, Rosenthal JT. (1993) Positron emission tomography: a new method for determination of renal function. J Urol. 150(3):1064-8.Klopper JF, Hauser W, Atkins HL, Eckelman WC, Richards P. (1972) Evaluation of Tc-99m DTPA for the measurement of glomerular filtration rate. J Nuc Med 1 3:107-110.Kade H, Meredith Om Jr, Taplin Gv, Winter Cc. (1956) The radioisotope renogram: an external test for individual kidney function and upper urinary tract patency. J Lab Clin Med. 48(6):886-901.Kimbel, K. H. (1956) Discussion of paper by W. Schlungbaum and H. Billion, in: Radioaktive isotope in Klinik und Forschung. VortrageGeisteinerIntSymp, Vol. 2 Urban Schwartzenburg, Berlin.9.Klingensmith WC, Tyler HN, Marsh WC, et al: Effect of hydration and dehydration on technetium-99m CO2DADS renal studies in normal volunteers. J Nucl Med 26:875-879, 1985.18.Lee HB, Blaufox MD: Renal functional response to captopril during diuretic therapy. J Nucl Med 33:739-743, 1992.Lagomarsino E, Orellana P, Munoz J , Velasque z C, Cavagnaro F, Valdes F. (2004) Captopril scintigraphy in the study of arterial hypertension in pediatrics . PediatrNephrol 19:66-70Laguna R, Silva F, Orduna E, Conway JJ, Weiss S, Calderon C, (1998) Technetium-99m-MAG3 in Early Identification of Pyelonephritis in Children. J Nucl Med 39(7): 1254-1257Lin WY, Wang SJ. Tc-99m DMSA imaging in kidney contusion. (1996) ClinNucl Med 21:144. 5.McBiles II M, Lambert A, Cote M, et al. Diuretic scintigraphy. Past, Present and Future. Nucl Med Ann 1995;185-216Moore EE, Shackford SR, Pachter HL, McAninch JW, Browner BD, Champion HR, Flint LM, Gennarelli TA, Malangoni MA, RamenofskyML,et al. (1989) Organ injury scaling: spleen, liver, and kidney. J Trauma. 29:1664 –1666.Nankivell BJ, Cohn DA, Spicer ST, Evans SG, Chapman JR, Gruenewald SM. (2001) Diagnosis of kidney transplant obstruction using Mag3 diuretic renography. Clin Transplant. 15(1):11-8.Ng CS, de Bruyn R, Gordon I (1997) The investigation of renovascular hypertension in children: the accuracy of radio-isotopes in detecting renovascular disease. Nucl Med Comm 8:101728.O’Malley JP, Ziessman HA, et al. Tc-99m MAG3 as an alternative to Tc-99m DTPA and I-131 hippuran for renal transplant evaluation. ClinNucl Med 1993; 18:22-29.12.Pediatric nuclear medicine council: The “well tempered’ diuretic renogram: A standard method to examine the asymptomatic neonate with hydronephrosis or hydroureteronephrosis. J Nucl Med 33:2047-2051, 1992.Pollack HM, Wein AJ. (1989) Imaging of renal trauma. Radiology 172:297-308.Rehling M, M?ller ML, Lund JO et al 1985. 99mTc-DTPA gamma-camera renography: normal values and rapid determination of single-kidney glomerular filtration rate. Eur J Nucl Med 11: 1-613.Rossleigh MA, Leighton DM, Farnsworth FH: Diuresis renography: The need for an additional view after gravity-assisted drainage. ClinNucl Med 18:210-213, 1993.Santucci RA, McAninch JW, Sa?r M, Mario LA, Service S, Segal MR. (2001) Validation of the American Association for the Surgery of Trauma organ injury severity scale for the kidney. J Trauma 50: 195–200.Schwartz GJ, Brion LP, Spitzer A. (1987) The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. PediatrClin North Am 34:571–590Schwartz GJ, Mu?oz A, Schneider MF, Mak RH, Kaskel F, Warady BA, Furth SL. (2009) New equations to estimate GFR in children with CKD . J Am SocNephrol. 20(3):629-637.Sfakianakis GN., Cavagnaro F, Zilleruelo G, Abitbol C, Montane B, Georgiou M, Ezuddin S, Mallin W, Sfakianakis E, Strauss J, (2000) Diuretic MAG3 Scintigraphy (F0) in Acute Pyelonephritis: Regional Parenchymal Dysfunction and Comparison with DMSA. J Nucl Med 41:1955-1963Shamlou KK, Drane WE, Hawkins IF, Fennell RS 3rd. (1994) Captopril renography and the hypertensive renal transplantation patient: a predictive test of therapeutic outcome. Radiology. 190(1):153-9.5.Shanahan WSM, Klingensmith WC, Weil R: Tc-99m-DTPA renal studies for acute tubular necrosis: Specificity of dissociation between perfusion and clearance. Am J Roentgenol 136:249-253, 1981.Shelton ME, Green MA, Mathias CJ, Welch MJ, Bergmann SR. (1990) Assessment of regional myocardial and renal blood ?ow with copper-PTSM and positron emission tomography. Circulation 82:990-997, 1990Sheth KJ, Sty JR, Johnson F, Tisdale P. (1984) Myoglobinuria with acute renal failure and hot kidneys seen on bone imaging. ClinNucl Med. 1984 9(9):498-501.30.SNM procedure guideline H, Heiba S, Kostakoglu L, Machac J. (2010) Extraperitoneal urine leak after renal transplantation: the role of radionuclide imaging and the value of accompanying SPECT/CT - a case report. BMC Med Imaging. 2010;10:23Staples A, LeBlond R, Watkins S, Wong C, Brandt J. (2010) Validation of the revised Schwartz estimating equation in a predominantly non-CKD population. PediatrNephrol. 25(11):2321-2326Szabo Z, Xia J, Mathews WB, Brown PR. (2006) Future direction of renal positron emission tomography. SeminNucl Med. 36(1):36-50.Tamaki N, Rabito CA, Alpert NM, Yasuda T, Correia JA, Barlai-Kovach M, Kanke M, Dragotakes SC, Strauss HW. (1986) Serial analysis of renal blood ?ow by positron tomography with rubidium-82. Am J Physiol. 251(5):H1024-1030Talanow R, Neumann D, Brunken R, Bybel B, Wu G. (2007) Urinary Leak After Renal Transplantation Proven by SPECT-CT Imaging. ClinNucl Med 32(11); 883-88526.Taylor A, Eshima D, et al. Comparison of iodine I-131 OIH and Tc-99m MAG3 renal imaging in volunteers. J Nucl Med 1986; 27795-803.Taylor A. (1999) Radionuclide renography: a personal approach. SeminNucl Med. 29(2):102-27.19.Tunny TJ, Klemm SA, Hamlet SM, et al: Diagnosis of unilateral renovascular hypertension: Comparative effect of intravenous enalaprilat and oral captopril. J Urol 140:713-715, 1988.Valdez VA, Jacobstein JG. (1980) Decreased bone uptake of technetium-99m polyphosphate in thalassemia major. J Nucl Med. 21(1):47-49.Wistow BW, McAfee JG, Sagerman RH. (1979) Renal uptake of Tc-99m MDP after radiation therapy. J Nucl Med 20: 32-34Klingensmith WC 3rd, Briggs DE, Smith WI. (1994) Technetium-99m-MAG3 Renal Studies: Normal Range and Reproducibility of Physiologic Parameters as a Function of Age and Sex J Nucl Med 1994 35:1612-1617 ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download